Catherine Cargo
A5078781310- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Otitis Media and Relapsing Polychondritis
- Cancer Genomics and Diagnostics
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Kruppel-like factors research
- Platelet Disorders and Treatments
- Acute Lymphoblastic Leukemia research
- Hematological disorders and diagnostics
- Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Inflammasome and immune disorders
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Vascular Anomalies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- Histiocytic Disorders and Treatments
- Epigenetics and DNA Methylation
- Protein Degradation and Inhibitors
- Renal Diseases and Glomerulopathies
- Congenital Ear and Nasal Anomalies
St James's University Hospital
2015-2025
Leeds Teaching Hospitals NHS Trust
2016-2025
University of Leeds
2019
Queen's University Belfast
2012
Peter MacCallum Cancer Centre
2011
University of Ulster
2008
Belfast City Hospital
2008
Royal College of Physicians and Surgeons of Glasgow
2006
Royal College of Physicians
2006
Abstract The myeloid neoplasms encompass acute leukemia, myelodysplastic syndromes and myeloproliferative neoplasms. Most cases arise from the shared ancestor of clonal hematopoiesis (CH). Here we analyze data 454,340 UK Biobank participants, whom 1,808 developed a neoplasm 0–15 years after recruitment. We describe differences in CH mutational landscapes hematology/biochemistry test parameters among individuals that later develop (pre-MN) versus controls, finding disease-specific changes are...
Population-based information on cancer incidence, prevalence and outcome are required to inform clinical practice research; but contemporary data lacking for many myeloid malignancy subtypes.Set within a socio-demographically representative UK population of ∼4 million, (N=5231 diagnoses) from an established patient cohort. Information survival (relative & overall), transformation/progression, is presented >20 subtypes.The median diagnostic age was 72.4years (InterQuartile Range 61.6-80.2),...
The fusion gene MLL/AF4 defines a high-risk subtype of pro-B acute lymphoblastic leukemia. Relapse can be associated with lineage switch from to myeloid leukemia, resulting in poor clinical outcomes caused by resistance chemotherapies and immunotherapies. In this study, the relapses shared oncogene breakpoints their matched lymphoid presentations originated various differentiation stages immature progenitors through committed B-cell precursors. Lineage switching is linked substantial changes...
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a recently described autoinflammatory disorder with little therapeutic evidence. We compared treatment outcomes of targeted therapies versus prednisolone alone in the largest UK cohort patients VEXAS to date. In this retrospective study, we analysed six tertiary referral centres across between July 22, 2014, and Oct 19, 2024. The inclusion criteria were genetically confirmed receipt at least one therapy or alone....
Determining the underlying cause of persistent eosinophilia is important for effective clinical management but remains a diagnostic challenge in many cases. We identified STAT5B N642H, an established oncogenic mutation, 27/1715 (1.6%) cases referred investigation eosinophilia. Of 27 mutated cases, working diagnosis hypereosinophilic syndrome (HES; n = 7) or myeloid neoplasm with (n 20) had been made prior to detection N642H. Myeloid panel analysis median 2 additional genes (range 0–4) 4...
Objective To assess the prevalence of MYD 88 L265P mutation and variants within NLRP 3 evaluate status oligoclonal hematopoiesis in 30 patients with Schnitzler syndrome (SchS). Methods Thirty SchS were recruited from clinical centers. Six known acquired cryopyrin‐associated periodic syndromes ( aCAPS ) included as controls. Allele‐specific oligonucleotide–polymerase chain reaction was used for detection variant, next‐generation sequencing applied to analyze 28 genes associated...
Population-based information on cancer incidence and outcome are required to inform clinical practice research; but contemporary data lacking for many lymphoid subtypes.
Advancements in comprehending myelodysplastic neoplasms (MDS) have unfolded significantly recent years, elucidating a myriad of cellular and molecular underpinnings integral to disease progression. While inclusions into prognostic models substantively advanced risk stratification, revelations emphasized the pivotal role immune dysregulation within bone marrow milieu during MDS evolution. Nonetheless, immunotherapy for has not experienced breakthroughs seen other malignancies, partly...
Summary The precise link between inflammation and pathogenesis of myelodysplastic syndrome (MDS) is yet to be fully established. We developed a novel method measure ASC/NLRP3 protein specks which are specific for the NLRP3 inflammasome only. combined this with cytokine profiling characterise various inflammatory markers in large cohort patients lower risk MDS comparison healthy controls defined autoinflammatory disorders (AIDs). were significantly elevated compared ( p < 0.001) these...
Objectives: We theorized that myelodysplastic syndrome (MDS) with somatic mutations and karyotype abnormalities are associated autoinflammation, the presence of autoinflammatory disease affected prognosis in MDS. Methods: One hundred thirty-four MDS patients were assessed for prevalence complications its link karyotypes mutation status. Autoinflammatory described either as well-defined diseases (AD) or undifferentiated “autoinflammatory disease” (UAD) (defined CRP over 10.0 mg/L on five...